Stage II Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female | Stage II

Stage II breast cancer survivor after chemotherapy, with ongoing survivorship advice focused on hair loss, neuropathy, fertility preservation, nausea, fatigue, chemo brain, and support.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland ClinicRead more →

Stage II Invasive Lobular Carcinoma: Tamra's Patient Story

Patient Info: Tamra, Female | Stage II

Biomarkers: MammaPrint genomic analysis pending/under consideration

As of January 2026, Tamra had chosen partial mastectomy with radiation and concurrent bilateral reconstruction for Stage II invasive lobular breast cancer, with chemotherapy decision dependent on MammaPrint results.

Lobular Breast Cancer AllianceRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Invasive lobular breast cancer with dense lymphocytic infiltration treated with surgery, radiation, chemotherapy, and endocrine therapy

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-positive/PR-negative, HER2 1+ lobular breast cancer; Ki-67 35%

At 1 year after surgery, the patient remained recurrence-free while receiving postmenopausal aromatase inhibitor endocrine therapy.

PubMed CentralRead more →

Stage IIA ER/PR-positive mucinous breast cancer: tamoxifen plus cryoablation with no recurrence

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: ER/PR strongly positive, HER2 negative; CA15-3 and CEA remained normal during follow-up.

At approximately 32 months after cryoablation, the treated area had decreased to a less distinct 0.7 cm scar-like region, with no evidence of recurrence in either breast, axillae, or distant sites.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Njathi, Female, 40s | Stage II

Biomarkers: Triple-positive; ER-positive; PR-positive; HER2-positive

As of October 2025, Jennifer was more than 1 year past treatment for triple-positive Stage IIA breast cancer and had a recent clear MRI.

City of HopeRead more →

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

Stage II Breast Cancer: Basma's Patient Story

Patient Info: Basma, Female, 40s | Stage II

As of October 2025, Basma had completed chemotherapy, tumor-removal surgery, and radiation with clear results and full recovery, while continuing daily oral medication and an injection every 3 months for prevention.

Stage II central breast cancer: oncoplastic breast-conserving surgery with hatchet and AICAP flaps

Patient Info: Anonymized, Female, 70+ | Stage II

She completed oncoplastic breast-conserving surgery and radiotherapy; 3 months after radiotherapy, the reconstructed breast remained soft with sufficient volume and favorable cosmetic results.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Stage II Invasive Ductal Carcinoma: Charlotte's Survivor Story

Patient Info: Charlotte, Female | Stage II

Biomarkers: BRCA inherited mutation negative

As of September 2025, Charlotte had undergone bilateral mastectomy, removal of 2 lymph nodes, delayed wound healing, and radiation for Stage II invasive ductal carcinoma, and was focused on recovery and life after treatment.

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage 2 secretory breast cancer: surgery alone with clear margins

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PR-negative; HER2-negative; secretory carcinoma; low grade

At 1-month follow-up after modified radical mastectomy, she had no surgical site infection, no arm lymphedema, no scapular winging, full shoulder range of motion, and no evidence of nodal or distant disease.

PubMed CentralRead more →

Stage II BRCA2 Invasive Ductal Carcinoma: Onjalai's Survivor Story

Patient Info: Onjalai Brown, Female, Under 40 | Stage II

Biomarkers: Patient-specific biomarker/genetic result not reported; family history suggests BRCA2 mutation

After lumpectomy, 20 rounds of chemotherapy and 36 rounds of radiation for Stage II invasive ductal carcinoma with lymph-node involvement, Onjalai had been cancer-free for 3 years as of May 2025.

City of HopeRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

HER2-amplified primary mucinous cystadenocarcinoma of the breast: surgery and adjuvant treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: HER2-amplified / HER2 3+; ER/PR-negative; Ki-67 ~50%; p53 high; microsatellite stable. No clinically significant inherited mutation reported.

As of November 2024, she had more than 104 months of disease-free survival after breast-conserving surgery, sentinel lymph node biopsy, EC-T chemotherapy, and radiotherapy for Stage IIA HER2-amplified primary mucinous cystadenocarcinoma of the breast.

PubMed CentralRead more →

Right Stage IIB ER/PR-positive breast cancer with left epithelioid MPNST: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the right breast cancer or the left epithelioid malignant peripheral nerve sheath tumor; she remained on anastrozole for the right breast cancer.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer With Severe Myelitis During Pembrolizumab Treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative, PR-negative, HER2-negative, germline PALB2 variation

Imaging showed a complete tumor response before surgery, and surgery 6 months later found no residual breast cancer or involved sentinel nodes.

PubMed CentralRead more →

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient StoryRead more →